Requirements regarding dose rate and exposure time for killing of tumour cells in beta particle radionuclide therapy

Por Carlsson, Jörgen, Eriksson, Veronika, Stenerlöw, Bo, Lundqvist, Hans
Publicado em 2006

Preclinical evaluation of a novel engineered recombinant human anti-CD44v6 antibody for potential use in radio-immunotherapy

Por Mortensen, Anja C., Spiegelberg, Diana, Haylock, Anna-Karin, Lundqvist, Hans, Nestor, Marika
Publicado no Int J Oncol (2018)

Lessons on Tumour Response: Imaging during Therapy with (177)Lu-DOTA-octreotate. A Case Report on a Patient with a Large Volume of Poorly Differentiated Neuroendocrine Carcinoma

Por Garske, Ulrike, Sandström, Mattias, Johansson, Silvia, Granberg, Dan, Lundqvist, Hans, Lubberink, Mark, Sundin, Anders, Eriksson, Barbro
Publicado em 2012

Prospective observational study of (177)Lu-DOTA-octreotate therapy in 200 patients with advanced metastasized neuroendocrine tumours (NETs): feasibility and impact of a dosimetry-g...

Por Garske-Román, Ulrike, Sandström, Mattias, Fröss Baron, Katarzyna, Lundin, Lars, Hellman, Per, Welin, Staffan, Johansson, Silvia, Khan, Tanweera, Lundqvist, Hans, Eriksson, Barbro, Sundin, Anders, Granberg, Dan
Publicado no Eur J Nucl Med Mol Imaging (2018)